Similar to our findings, recent work has also demonstrated the utility of combining SRC and MEK inhibitors in the ovarian cancer setting [52], where the combination of selumetinib and saracatinib abolished Rac-1 mediated EMT of ovarian cancer cells. Here, SRC is linked to ovarian cancer.